---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-028994"
form_type: "8-K"
ticker: "AZTR"
cik: "0001701478"
company_name: "Azitra, Inc."
filed_at: "2026-06-17T12:05:40+00:00"
generated_at: "2026-06-17T12:12:35.050121+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Azitra CEO details strategic pivot to cosmetic ingredients and recombinant proteins; pauses Netherton trial

## Summary
- Raised $10.5M in March with up to $21M additional from warrant exercises to fund new initiatives.
- Launches ATR-COSF, a recombinant filaggrin cosmetic ingredient; expects clinical study completion in late 2026.
- In-licenses FHCC minicircle plasmids showing 100,000x improvement; targets TEV protease and T7 RNA Polymerase market (~$1B).
- ATR-04 (EGFR inhibitor rash) continues enrollment with MD Anderson as new clinical site.
- Pauses ATR-12 Netherton trial enrollment to redirect capital to ATR-COSF near-term milestones.

## SEC filing metadata
- accession: 0001493152-26-028994
- form_type: 8-K
- ticker: AZTR
- cik: 0001701478
- company_name: Azitra, Inc.
- filed_at: 2026-06-17T12:05:40+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701478/000149315226028994/0001493152-26-028994-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701478/000149315226028994/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-028994
- JSON: https://secwatch.observer/filing/0001493152-26-028994.json
- Plain text: https://secwatch.observer/filing/0001493152-26-028994.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.